Sign in

or Register now

MultipleSclerosisCentral.com

    See all of our health sites at www.HealthCentral.com
    Saturday, November 21, 2009
    • Font size
    • Bookmark
    • Save
    Receive a FREE Osteoarthritis of the knee pamphlet. Start here.

    Drugmaker says its MS drug reduces relapses

    (Reuters) UPDATED 2009-10-05
    According to drugmaker Novartis, their experimental MS drug FTY720 reduces relapses and disability progression. Researchers found that a low dose of 0.5 mg appeared to help MS patients. Experts say the company is on schedule to apply for U.S. Food and Drug Administration approval in December 2009.  Read full story >
    See all Multiple Sclerosis News
    • Font size
    • Bookmark
    • Was this helpful? Yes
    • Save

    People who read this also read...

      Note: All clinical content on this site is physician-reviewed, except material generated by our community members.
      Featuring Content From:
      • Harvard Health Publications
      • A.D.A.M.
      • Thomson PDR
      • Ivanhoe Broadcast News

      By using this service, you accept our Terms of Use. Please read them. The consumer health information on MultipleSclerosisCentral.com is for informational purposes only and is not a substitute for medical advice or treatment for any medical conditions. You should promptly seek professional medical care if you have any concern about your health, and you should always consult your physician before starting a fitness regimen. Copyright © 2005-2009. The HealthCentral Network, Inc. All rights reserved.

      This website is accredited by Health On the Net Foundation. Click to verify.We comply with the HONcode standard for trustworthy health information: verify here.
      • TRUSTe Certified Privacy
      • Health Care Standard of Excellence
      • FREDDIE International Health and Medical Media Award Finalist